{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-072992","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.833121+00:00","generated_at":"2026-05-17T21:47:22.301321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocugen reports Q2 2025 results; cash $27.3M; initiates OCU410ST Phase 2/3 trial","bullets":["Cash, cash equivalents and restricted cash $27.3M as of June 30, 2025, down from $58.8M at Dec 31, 2024; cash runway into Q1 2026.","Net loss $0.05 per share for Q2 2025, compared to $0.06 per share in Q2 2024; total operating expenses $15.2M.","Initiated dosing in Phase 2/3 GARDian3 trial for OCU410ST (Stargardt disease) after FDA clearance; received Rare Pediatric Disease Designation.","Signed binding term sheet for exclusive Korean rights to OCU400 with up to $11M in upfront and milestone payments.","Announced planned reverse merger of OrthoCellix with Carisma to spin off NeoCart, with OrthoCellix valued at $135M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-072992","json":"https://secwatch.observer/filing/0001104659-25-072992.json","markdown":"https://secwatch.observer/filing/0001104659-25-072992.md","text":"https://secwatch.observer/filing/0001104659-25-072992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/0001104659-25-072992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/tm2522209d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:47:22.301321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}